The bone and mineral complications associated with renal failure are numerous-hyperparathyroidism, adynamic bone disease, aluminum bone disease, acidosis, ␤ 2 -microglobulin amyloidosis, gonadal deficiencyassociated osteopenia, and posttransplant osteoporosis. Renal osteodystrophy is the generic term generally used to describe the skeletal complications of renal failure. Renal osteodystrophy encompasses a wide spectrum of bone disorders and is often classified on the basis of the predominant histopathologic patterns. Several classification schemes have been used. Traditionally five major histopathologic patterns are described: osteitis fibrosa, mild lesion, osteomalacia, mixed uremic osteodystrophy, and adynamic bone disease. Others (1) proposed dividing the disorders into three major groups: predominant hyperparathyroid bone disease (including osteitis fibrosa and mild disease), low-turnover uremic osteodystrophy (including osteomalacia and adynamic bone disease), and mixed uremic osteodystrophy (mild to moderate hyperparathyroidism with defective mineralization).
Osteitis fibrosa (predominant hyperparathyroid bone disease) is characterized by a marked increase in bone turnover as assessed by an elevated bone formation rate, increased remodeling (both formation and resorption), and peritrabecular fibrosis. It appears to be decreasing in frequency and has been reported in 5-50% of patients (1) (2) (3) (4) (5) . The primary metabolic abnormality with this lesion is long-standing hyperparathyroidism. Although hyperparathyroidism is common early in the development of renal failure, osteitis fibrosa is relatively rare prior to the development of end-stage renal disease (ESRD).
The mild lesion is characterized by a slight increase in the bone formation rate and remodeling, but is generally without significant peritrabecular fibrosis. It is the most common lesion seen prior to the development of ESRD (6) and has been increasing in frequency in dialysis patients, accounting for approximately 3-20% of patients (1) (2) (3) (4) (5) . It is usually the result of mild or early secondary hyperparathyroidism or follows therapy for hyperparathyroidism.
Osteomalacia is defined by a defect in mineralization with increased osteoid formation; however, bone formation is decreased, thus it is a low-turnover lesion. Aluminum intoxication, iron intoxication, severe vitamin D deficiency, plus other unidentified factors probably play a role in its pathogenesis. It is decreasing in frequency and is seen in approximately 4-8% of patients (1) (2) (3) (4) (5) 7) .
Features of osteomalacia with increased bone formation characterize the lesion of mixed uremic osteodystrophy. These features may coexist in varying degrees in different patients. Although there is no identifiable predominant cause, it appears to be secondary to hyperparathyroidism with a defect in mineralization. Aluminum or other unidentified factors may also be involved. This lesion may be found in 11-80% of patients (1) (2) (3) (4) (5) .
Adynamic bone disease (low turnover) represents the opposite end of the spectrum from osteitis fibrosa. It is characterized by a marked decrease in both remodeling and mineralization. There is a profound decrease in both osteoblasts and osteoclasts, and sites of active bone formation are rarely observed. The clinical significance of adynamic bone disease is controversial; however, it is associated with a propensity for hypercalcemia, extraskeletal calcifications, and a decreased ability of bone to buffer calcium (8, 9) . Although there are identifiable risk factors associated with adynamic bone disease, the pathogenesis is poorly understood. The frequency has been increasing and is observed in 25-60% of patients (1-5, 7, 10) . It is associated with relatively low levels of parathyroid hormone (after parathyroidectomy, overly aggressive medical management), aluminum intoxication, diabetes, and peritoneal dialysis (1, 2, 5, 10, 11) .
The current therapeutic approach to renal bone disease is to normalize the defect in bone remodeling. Thus it may be useful to classify renal osteodystrophy on the basis of being either a high-or low-turnover lesion ( Table 1 ). The high-turnover lesions include predominant hyperparathyroid bone disease (osteitis fibrosa), the mild lesion, and the subset of those with mixed uremic osteodystrophy with increased bone formation. The lowturnover lesions include the adynamic (both aluminumand non-aluminum-associated) and osteomalacia (both aluminum-and non-aluminum-associated). It needs to be appreciated that in any patient, transformation from one lesion to another may occur.
Therapy has predominantly focused on treating and or preventing the high-turnover lesion, which results from hyperparathyroidism. Thus parathyroid hormone (PTH) levels have become the surrogate measure of bone disease. In patients with markedly elevated PTH levels (>600-800 pg/ml), the diagnosis is rather obvious and therapy focuses on reducing PTH levels. In the rare patients who have had significant exposure to aluminum, aggressive therapy, especially parathyroidectomy, may unmask aluminum bone disease. Thus the diagnosis of underlying aluminum bone disease should be entertained in these patients. Unfortunately serum aluminum levels may not be helpful and the deferoxamine infusion test is not a reliable diagnostic test, making bone biopsies a necessity (12) . A specific histologic diagnosis may not be important in patients who have relatively low PTH levels (<100 pg/ml). These patients have either normal or low bone turnover, which would not require specific therapy to reduce PTH levels (13) .
It is in patients with intermediate PTH levels that a specific diagnosis may be most important. Multiple studies have shown that the circulating PTH concentration does not necessarily reflect the rate of bone turnover (4, (13) (14) (15) (16) . Furthermore, it has become apparent that a single measurement of PTH does not provide sufficient information to make a definitive diagnosis. The insensitivity of PTH in predicting bone formation rate is greatest in patients who have PTH values between 100 and 400 pg/ml. This encompasses the range of serum PTH concentrations (100-250 pg/ml) most nephrologist target as a therapeutic goal. In most of these patients, both radiographs and bone mineral densitometry are generally too insensitive to provide additional useful diagnostic information. It is in this group of patients that additional noninvasive diagnostic tests, such as biochemical markers, would be useful to direct therapy.
Biochemical markers of bone metabolism may be subdivided into two major categories reflecting either bone formation or resorption (Table 2) . Total alkaline phosphatase is the most commonly used marker of bone formation, but it lacks both sensitivity and specificity. In renal failure it is not possible to determine the relative contribution of the osseous, hepatic, and intestinal isoenzymes to the total alkaline phosphatase because of alterations in their respective half-lives.
The development of radioimmunologic and immunoenzymatic assays utilizing a monoclonal antibody against bone alkaline phosphatase has resulted in sensitive methods for measuring bone-specific alkaline phosphatase (BAP) in both normal and uremic patients (17) (18) (19) . In dialysis patients, BAP correlates well with both serum PTH concentrations and bone histomorphometry (17, (19) (20) (21) . When the BAP level is greater than 25 ng/ml, the specificity for high bone turnover is 92-100% (19, 21) ; however, the sensitivity is only about 70%. Thus, while few patients with low turnover have increased BAP, many patients with increased turnover do not have increased BAP. Unfortunately the addition of an elevated PTH level to the BAP does not increase the sensitivity or specificity for the diagnosis of high bone turnover (19, 21) . Prediction of low bone turnover by plasma BAP is even less precise. Three biopsy-based studies have evaluated the predictive value of a low BAP for adynamic bone disease. Although the studies employed different methods for measuring BAP and were limited by the low number of patients with adynamic bone disease, it appears that the combination of PTH levels less than 150 pg/ml and BAP levels less than 8 ng/ml has a positive predictive value of 70-75% (17, 20, 22) .
Osteocalcin or bone Gla protein (protein containing ␥-carboxyglutamic acid) is the most abundant noncollagenous protein in bone (23) . Osteocalcin is produced by osteoblasts under the regulation of 1,25-vitamin D. It can be released from the bone matrix during resorption and from osteoblasts during formation. Osteocalcin circulates in several forms and is cleared by the kidneys, thus its use in uremia has been limited (21, 24, 25) . In spite of these limitations, osteocalcin can help differentiate patients with high and low turnover (21), though it is not useful in differentiating patients with adynamic bone disease from those with normal bone turnover (25, 26) . Although plasma osteocalcin levels correlate with bone histomorphometric parameters in dialysis patients, the correlation is much weaker than BAP (20, 27) .
Another protein, procollagen type I C-terminal extension peptide (PICP), is produced by osteoblasts as the cleavage by-product of type I procollagen as it is incorporated into the bone matrix (28) . PICP is degraded in the liver and levels do not appear to be affected by renal failure or dialysis (29) . Patients with renal failure have increased levels that do not, however, correlate with other humoral markers of bone turnover or bone histomorphometry (29, 30) .
The clinical utility of markers of bone resorption in renal failure has yet to be established. It has been suggested that serum levels of tartrate-resistant acid phosphatase (TRAP), a lysosomal enzyme produced by osteoclasts, may correlate with bone resorption (31). However, studies have yet to be performed in uremic patients. Type I collagen cross-linked telopeptide (ICTP) is a small fragment of type I collagen that is released during bone resorption. The few studies performed in dialysis patients have not supported its use as a humoral marker of bone remodeling (27, 32) . Pyridinoline and deoxypyridinoline are two of the main collagen intermolecular cross-link molecules that are liberated into the plasma during bone resorption (33) . The measurement of these components in urine is widely used in patients with normal renal function. Studies have shown that serum levels of these components correlate with PTH, osteocalcin, and BAP (27, 34) . Routine serum assays are not yet available and additional studies are required to determine the usefulness of these assays. For the clinician, the question remains as to when is it clinically appropriate to perform a bone biopsy for an accurate diagnosis (Table 3 ). This decision should be based on the presence of symptomatic manifestations and whether the possibility of aluminum accumulation exists. In the symptomatic patient-those with fractures, myopathy, hypercalcemia, and extraskeletal calcifications-the major differential is between severe hyperparathyroidism and aluminum bone disease. Clearly if PTH levels are not markedly elevated or there is no other clinical evidence of osteitis fibrosa (increased alkaline phosphatase, radiographic findings), a biopsy should be performed. If a parathyroidectomy is contemplated, then aluminum disease has to be ruled out, and a biopsy is indicated. In the asymptomatic patient, the decision is much more difficult. If PTH levels are relatively low (<200-300 pg/ml), specific anti-PTH therapy is probably not warranted, thus a specific diagnosis is not necessary. However, if the patient develops hypercalcemia or has extraskeletal calcifications, either high-or low-turnover disease may be present and a biopsy may be required. For those patients with PTH levels between 250 and 500 pg/ml, treatment is usually directed at preventing the Abbreviations: glomerulonephritis (GN), peritoneal dialysis (PD), hemodialysis (HD), aluminum hydroxide (AlOH), aluminum (Al), calcium (Ca), phosphorus (P), alkaline phosphatase (AP), parathyroid hormone (PTH). development of parathyroid hyperplasia and reducing PTH levels. However, these patients are at greatest risk of developing adynamic bone disease. Thus if hypercalcemia occurs, a biopsy should be considered. Table 4 illustrates several clinical examples of when a biopsy may be helpful.
Although noninvasive techniques may be useful for evaluating and monitoring many patients, they have not proved to be specific or sensitive enough to accurately diagnose all patients. Bone biopsy remains the gold standard for the classification of renal bone disease and for determining optimal therapy. As we further understand the pathogenesis of renal bone diseases and develop new therapies for these diseases, a precise diagnosis may become necessary. Currently bone biopsies are the most precise and accurate diagnostic tool available to access bone disease. Until better noninvasive monitoring techniques are developed, biopsies should be performed in appropriate patients.
